de Morgan Stanley Agios Pharmaceuticals AGIO Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 35.7 M | Vender |
963,256
-4,269
| -0.4% | -USD 130 k | ﹤0.01% | 2541 |
|
|
2026
Q1 | USD 32.7 M | Comprar |
967,525
+73,488
| +8% | +USD 2.08 M | ﹤0.01% | 2510 |
|
|
2025
Q4 | USD 24.3 M | Comprar |
894,037
+477,039
| +114% | +USD 16.7 M | ﹤0.01% | 2749 |
|
|
2025
Q3 | USD 16.7 M | Comprar |
416,998
+125,033
| +43% | +USD 4.7 M | ﹤0.01% | 3051 |
|
|
2025
Q2 | USD 9.7 M | Vender |
291,965
-2,658
| -0.9% | -USD 80.6 k | ﹤0.01% | 3468 |
|
|
2025
Q1 | USD 8.63 M | Vender |
294,623
-83,466
| -22% | -USD 2.77 M | ﹤0.01% | 3474 |
|
|
2024
Q4 | USD 12.4 M | Comprar |
378,089
+29,116
| +8% | +USD 1.37 M | ﹤0.01% | 3222 |
|
|
2024
Q3 | USD 15.5 M | Vender |
348,973
-247,702
| -42% | -USD 11.2 M | ﹤0.01% | 3053 |
|
|
2024
Q2 | USD 25.7 M | Vender |
596,675
-583,651
| -49% | -USD 21.1 M | ﹤0.01% | 2391 |
|
|
2024
Q1 | USD 34.5 M | Comprar |
1,180,326
+686,739
| +139% | +USD 18.4 M | ﹤0.01% | 2111 |
|
|
2023
Q4 | USD 11 M | Comprar |
493,587
+119,458
| +32% | +USD 2.68 M | ﹤0.01% | 3244 |
|
|
2023
Q3 | USD 9.26 M | Vender |
374,129
-17,338
| -4% | -USD 459 k | ﹤0.01% | 3196 |
|
|
2023
Q2 | USD 11.1 M | Comprar |
391,467
+80,685
| +26% | +USD 2.01 M | ﹤0.01% | 3056 |
|
|
2023
Q1 | USD 7.14 M | Vender |
310,782
-55,737
| -15% | -USD 1.48 M | ﹤0.01% | 3452 |
|
|
2022
Q4 | USD 10.3 M | Comprar |
366,519
+86,988
| +31% | +USD 2.45 M | ﹤0.01% | 3058 |
|
|
2022
Q3 | USD 7.91 M | Vender |
279,531
-136,605
| -33% | -USD 3.66 M | ﹤0.01% | 3206 |
|
|
2022
Q2 | USD 9.22 M | Comprar |
416,136
+85,605
| +26% | +USD 1.93 M | ﹤0.01% | 3148 |
|
|
2022
Q1 | USD 9.6 M | Comprar |
330,531
+72,595
| +28% | +USD 2.22 M | ﹤0.01% | 2944 |
|
|
2021
Q4 | USD 8.48 M | Comprar |
257,936
+81,643
| +46% | +USD 3.29 M | ﹤0.01% | 3127 |
|
|
2021
Q3 | USD 8.14 M | Vender |
176,293
-108,475
| -38% | -USD 5.24 M | ﹤0.01% | 3139 |
|
|
2021
Q2 | USD 15.7 M | Vender |
284,768
-79,626
| -22% | -USD 4.45 M | ﹤0.01% | 2436 |
|
|
2021
Q1 | USD 18.8 M | Comprar |
364,394
+142,214
| +64% | +USD 7.04 M | ﹤0.01% | 1979 |
|
|
2020
Q4 | USD 9.6 M | Vender |
222,180
-221,528
| -50% | -USD 8.76 M | ﹤0.01% | 2549 |
|
|
2020
Q3 | USD 15.5 M | Comprar |
443,708
+393,452
| +783% | +USD 17.2 M | ﹤0.01% | 1661 |
|
|
2020
Q2 | USD 2.69 M | Vender |
50,256
-72,128
| -59% | -USD 3.34 M | ﹤0.01% | 3309 |
|
|
2020
Q1 | USD 4.34 M | Vender |
122,384
-31,285
| -20% | -USD 1.45 M | ﹤0.01% | 2596 |
|
|
2019
Q4 | USD 7.34 M | Comprar |
153,669
+130,680
| +568% | +USD 4.94 M | ﹤0.01% | 2772 |
|
|
2019
Q3 | USD 744 k | Vender |
22,989
-56,567
| -71% | -USD 2.34 M | ﹤0.01% | 4472 |
|
|
2019
Q2 | USD 3.97 M | Comprar |
79,556
+21,107
| +36% | +USD 1.13 M | ﹤0.01% | 3155 |
|
|
2019
Q1 | USD 3.94 M | Vender |
58,449
-20,237
| -26% | -USD 1.18 M | ﹤0.01% | 2937 |
|
|
2018
Q4 | USD 3.63 M | Comprar |
78,686
+28,737
| +58% | +USD 1.77 M | ﹤0.01% | 3251 |
|
|
2018
Q3 | USD 3.85 M | Vender |
49,949
-39,251
| -44% | -USD 3.16 M | ﹤0.01% | 3456 |
|
|
2018
Q2 | USD 7.51 M | Comprar |
89,200
+20,827
| +30% | +USD 1.82 M | ﹤0.01% | 2701 |
|
|
2018
Q1 | USD 5.59 M | Comprar |
68,373
+13,534
| +25% | +USD 1.05 M | ﹤0.01% | 2905 |
|
|
2017
Q4 | USD 3.14 M | Vender |
54,839
-48,073
| -47% | -USD 3.02 M | ﹤0.01% | 3599 |
|
|
2017
Q3 | USD 6.87 M | Comprar |
102,912
+26,737
| +35% | +USD 1.61 M | ﹤0.01% | 2636 |
|
|
2017
Q2 | USD 3.92 M | Comprar |
76,175
+11,840
| +18% | +USD 605 k | ﹤0.01% | 3133 |
|
|
2017
Q1 | USD 3.76 M | Vender |
64,335
-19,537
| -23% | -USD 937 k | ﹤0.01% | 3174 |
|
|
2016
Q4 | USD 3.5 M | Vender |
83,872
-14,211
| -14% | -USD 746 k | ﹤0.01% | 3357 |
|
|
2016
Q3 | USD 5.18 M | Vender |
98,083
-8,821
| -8% | -USD 384 k | ﹤0.01% | 2622 |
|
|
2016
Q2 | USD 4.48 M | Vender |
106,904
-12,626
| -11% | -USD 624 k | ﹤0.01% | 2722 |
|
|
2016
Q1 | USD 4.85 M | Vender |
119,530
-20,003
| -14% | -USD 855 k | ﹤0.01% | 2561 |
|
|
2015
Q4 | USD 9.06 M | Vender |
139,533
-1,107
| -0.8% | -USD 72.6 k | ﹤0.01% | 2073 |
|
|
2015
Q3 | USD 9.9 M | Vender |
140,640
-26,136
| -16% | -USD 2.55 M | ﹤0.01% | 1954 |
|
|
2015
Q2 | USD 18.5 M | Vender |
166,776
-21,165
| -11% | -USD 2.28 M | 0.01% | 1565 |
|
|
2015
Q1 | USD 17.7 M | Vender |
187,941
-43,295
| -19% | -USD 4.85 M | 0.01% | 1557 |
|
|
2014
Q4 | USD 25.9 M | Comprar |
231,236
+20,927
| +10% | +USD 1.87 M | 0.01% | 1266 |
|
|
2014
Q3 | USD 12.9 M | Vender |
210,309
-1,215
| -0.6% | -USD 52.4 k | 0.01% | 1802 |
|
|
2014
Q2 | USD 9.7 M | Comprar |
211,524
+10,023
| +5% | +USD 409 k | ﹤0.01% | 2062 |
|
|
2014
Q1 | USD 7.89 M | Comprar |
201,501
+5,302
| +3% | +USD 177 k | ﹤0.01% | 2151 |
|
|
2013
Q4 | USD 4.7 M | Vender |
196,199
-86,708
| -31% | -USD 1.98 M | ﹤0.01% | 2626 |
|
|
2013
Q3 | USD 7.91 M | Comprar |
+282,907
| Nuevas | +USD 7.81 M | ﹤0.01% | 1980 |
|
Otros fondos que tienen AGIO en su cartera
LCM
Posición de Morgan Stanley en AGIO: resumen de T2 2026
Morgan Stanley redujo su participación en Agios Pharmaceuticals (AGIO) en 0.44% durante T2 2026, al vender acciones por un valor estimado de USD 130 k, y conservó 963,256 acciones valuadas en USD 35.7 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #2541.
Morgan Stanley reportó por primera vez una posición en AGIO en T3 2013 y la ha mantenido durante 52 trimestres desde entonces. Al cierre de T2 2026, 238 fondos que sigue Wall St. Rank mantienen una posición en AGIO.
- Al cierre de T2 2026, Morgan Stanley tenía 963,256 acciones de Agios Pharmaceuticals con un valor de USD 35.7 M.
- Morgan Stanley vendió 4,269 acciones de Agios Pharmaceuticals en T2 2026, por un valor estimado de USD 130 k.
- Agios Pharmaceuticals representó ﹤0.01% de la cartera de Morgan Stanley en T2 2026 y fue su posición número 2541.
- Morgan Stanley reportó por primera vez una posición en Agios Pharmaceuticals en T3 2013 y la ha mantenido durante 52 trimestres desde entonces.
- Al cierre de T2 2026, 238 fondos que sigue Wall St. Rank tenían Agios Pharmaceuticals en cartera.
Según el Informe 13F de Morgan Stanley correspondiente a T2 2026, presentado el 13 ago 2026.